Valuation: CellSource Co., Ltd.

Market Cap 6.91B 43.27M 37.39M 35.16M 31.98M 60.12M 4.14B 61.1M 409M 161M 2.08B 163M 159M P/E 2026 *
116x
P/E 2027 * 63.3x
Enterprise Value 6.91B 43.27M 37.39M 35.16M 31.98M 60.12M 4.14B 61.1M 409M 161M 2.08B 163M 159M EV / Sales 2026 *
1.92x
EV / Sales 2027 * 1.82x
Free-Float
45.73%
Yield 2026 *
-
Yield 2027 * -
1 day-2.52%
1 week+5.45%
Current month+8.07%
1 month+1.75%
3 months-4.13%
6 months-12.78%
Current year-12.78%
1 week 318
Extreme 318
357
1 month 307
Extreme 307
357
Current year 294
Extreme 294
442
1 year 294
Extreme 294
666
3 years 294
Extreme 294
2,600
5 years 294
Extreme 294
8,160
10 years 294
Extreme 294
8,160
Manager TitleAgeSince
Chief Executive Officer 62 2025-10-31
Director of Finance/CFO - 2025-12-31
Corporate Officer/Principal - 2023-12-31
Director TitleAgeSince
Director/Board Member 64 2017-05-31
Chairman 62 2024-01-24
Director/Board Member 57 2022-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-2.52%+5.45%-48.29%-83.81% 44.47M
+0.65%+0.27%+39.60%+1.70% 80.48B
-1.10%-2.42%-3.61%+28.98% 50.63B
+0.88%-3.47%+12.88%+166.89% 47.57B
+17.25%+17.36%-41.63%-41.46% 45.84B
+1.63%+2.62%+53.35%-18.72% 30.9B
-2.33%+5.27%+124.70%-40.74% 25.73B
-0.02%+1.58%+42.05%+92.29% 25.03B
+1.36%-0.67%-0.87%+195.57% 21.16B
+1.49%+3.15%+69.69%+123.80% 16.75B
Average +2.09%+0.89%+24.79%+42.45% 34.41B
Weighted average by Cap. +2.81%-0.61%+25.47%+42.23%

Financials

2026 *2027 *
Net sales 3.6B 22.55M 19.49M 18.32M 16.67M 31.34M 2.16B 31.85M 213M 84.02M 1.08B 84.7M 82.85M 3.8B 23.81M 20.57M 19.34M 17.59M 33.08M 2.28B 33.62M 225M 88.69M 1.14B 89.41M 87.46M
Net income 60M 376K 325K 305K 278K 522K 35.96M 531K 3.55M 1.4M 18.03M 1.41M 1.38M 110M 689K 595K 560K 509K 958K 65.92M 973K 6.52M 2.57M 33.05M 2.59M 2.53M
Net Debt - -
Logo CellSource Co., Ltd.
CellSource Co., Ltd. is a Japan-based company engaged in regenerative medicine related business and consumer business. The Company operates in two business segments. The Regenerative Medicine Related business segment is engaged in the provision of contracted services for processing tissues and cells derived from fat and blood to medical institutions, and support services for regenerative medicine laws and regulations related to safety assurance such as regenerative medicine, as well as sales of medical equipment. The Consumer business segment is engaged in the sales of cosmetics and facial products to general consumers.
Employees
148
Date Price Change Volume
26-08-18 JP¥348.00 -2.52% 45,600
26-08-17 JP¥357.00 +2.59% 80,600
26-08-14 JP¥348.00 +1.46% 36,800
26-08-13 JP¥343.00 +3.63% 39,900
26-08-12 JP¥331.00 +0.30% 21,300
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4880 Stock